Background: Schizophrenia is a chronic mental disorder, characterized byacute exacerbation and remission phases. Immune system has a role in the pathophysiology of schizophrenia. High mobility group box-1 (HMGB-1) is a macrophage secreted protein activating immune cells to produce cytokines. The aim of this study was to evaluate HMGB-1 levels among patients with schizophrenia both in acute exacerbation and remission phases. Methods: Consecutive schizophrenia patients in acute exacerbation and remission phases were enrolled and compared with each other and with age-sex matched healthy subjects. Patients were assessed with the Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms (SANS), Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression Scale (CGI). Results: Mean HMGB-1 levels were not significantly different in acute exacerbation phase versus remission phase schizophrenia patients (2.139±0.564 g/L vs. 2.326± 0.471 g/L, p=0.335) and both were individually higher than the control group (1.791±0.444 g/L, p=0.05 for acute exacerbation vs control, p=0.002 for remission vs control). In remission phase schizophrenic patients, HMGB-1 levels were positively correlated with Scale For The Assessment of Positive Symptoms (r=0.447, p=0.015) and BPRS (r=0.397, p=0.033) scores and HMGB-1 levels were independently associated with BPRS. Conclusions: Serum HMGB-1 levels were shown to be increased in patients with schizophrenia patients irrespective of phase, there were no differences between patients in acute exacerbation and remission phase in terms of biomarker and HMGB-1 levels were related to symptom severity according to psychiatric scales among patients in remission phase of schizophrenia.

中文翻译：

---

精神分裂症中的高迁移率族 box-1 水平：缓解期的潜在生物标志物。


背景：精神分裂症是一种慢性精神障碍，其特征为急性加重期和缓解期。免疫系统在精神分裂症的病理生理学中发挥作用。高迁移率族盒-1 (HMGB-1) 是一种巨噬细胞分泌的蛋白质，可激活免疫细胞产生细胞因子。本研究的目的是评估精神分裂症患者急性加重期和缓解期的 HMGB-1 水平。方法：连续入组处于急性加重期和缓解期的精神分裂症患者，并进行相互比较以及与年龄性别匹配的健康受试者进行比较。使用阳性症状评估量表（SAPS）、阴性症状评估量表（SANS）、简明精神病评定量表（BPRS）、临床总体印象量表（CGI）对患者进行评估。结果：急性加重期与缓解期精神分裂症患者的平均 HMGB-1 水平没有显着差异（2.139±0.564 g/L vs. 2.326±0.471 g/L，p=0.335），并且均高于对照组（ 1.791±0.444 g/L，急性加重与控制相比，p=0.05，缓解与控制相比，p=0.002）。在缓解期精神分裂症患者中，HMGB-1水平与阳性症状评估量表（r=0.447，p=0.015）和BPRS（r=0.397，p=0.033）评分呈正相关，并且HMGB-1水平独立相关与BPRS。结论：无论处于哪个阶段，精神分裂症患者的血清 HMGB-1 水平均升高，急性加重期和缓解期患者的生物标志物没有差异，并且根据精神科，HMGB-1 水平与症状严重程度相关。精神分裂症缓解期患者的量表。